Among adults with chronic pain, people with certain types of pain are more vulnerable to depression and anxiety.

New research shows an AI-powered chatbot trained to deliver cognitive behavioral therapy significantly reduced anxiety, ...

A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

Shares of biopharmaceutical company Axsome Therapeutics (NASDAQ: AXSM) had declined 6% at 11 a.m. ET today. The slump comes ...

Axsome Therapeutics (AXSM) announced results of the PARADIGM Phase 3 proof-of-concept trial of solriamfetol in major depressive disorder, MDD, ...

Axsome Therapeutics posted mixed results for its experimental depression treatment on Tuesday, leading Axsome stock to dive.

In light of these findings, Axsome has announced plans to initiate a Phase 3 trial focusing exclusively on MDD patients with EDS in 2025. This decision comes after observing clinically meaningful and ...

Axsome Therapeutics said on Tuesday it will narrow the focus of a late-stage study of its depression drug after an initial run of the trial showed improvement only in a small subgroup of patients. The ...

Recent federal funding cuts to substance abuse and mental health programs threaten to deepen an already dire crisis. The ...

Learn more about whether Corcept Therapeutics Incorporated or Intra-Cellular Therapies, Inc. is a better investment based on ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company developing breakthrough therapeutics for neurologic and neuropsychiatric disorders, today announced the enrollment of ...

Recent federal funding cuts to substance abuse and mental health programs threaten to deepen an already dire crisis. The ...